On 2015 Dec 18, Ahmed Adeel commented:

The figures for the therapeutic efficacy of AS/SP in this article need to be clarified. The ABSTRACT says: "PCR corrected per-protocol efficacy was 93.7%." Then in the DISCUSSION it is 90.5%:Page5 column2, they say “In the present study the in vivo per-protocol PCR corrected efficacy of AS/SP over 28 days is 90.5%.” The paper does not show how the figure of 90.5% was calculated.

Do they mean 90.5% rather than 93.7% .They make reference to a previous study in which they reported the figure of 93% for cure rate with AS/SP in a 2004-2005 study .They say (in 2013 paper ) (page 5,column 2 line8):

“..while we have reported a base-line PCR corrected efficacy of 93% [57]. "

According to its title the paper is about "declining artesunate/sulphadoxine-pyrimethamine efficacy...". However, the figure of “90.5 %" is more in line with a decline than "93.7%", because 93.7% is not declining from 93 %. Moreover, in this paper they say: “Approximately 10% of patients exhibited recrudescing parasites as confirmed by msp1 and msp2 genotyping during the study.” Approximately 10% is closer to 90.5% than 93.7%.

On 2015 Dec 18, Ahmed Adeel commented:

The figures for the therapeutic efficacy of AS/SP in this article need to be clarified. The ABSTRACT says: "PCR corrected per-protocol efficacy was 93.7%." Then in the DISCUSSION it is 90.5%:Page5 column2, they say “In the present study the in vivo per-protocol PCR corrected efficacy of AS/SP over 28 days is 90.5%.” The paper does not show how the figure of 90.5% was calculated.

Do they mean 90.5% rather than 93.7% .They make reference to a previous study in which they reported the figure of 93% for cure rate with AS/SP in a 2004-2005 study .They say (in 2013 paper ) (page 5,column 2 line8):

“..while we have reported a base-line PCR corrected efficacy of 93% [57]. "

According to its title the paper is about "declining artesunate/sulphadoxine-pyrimethamine efficacy...". However, the figure of “90.5 %" is more in line with a decline than "93.7%", because 93.7% is not declining from 93 %. Moreover, in this paper they say: “Approximately 10% of patients exhibited recrudescing parasites as confirmed by msp1 and msp2 genotyping during the study.” Approximately 10% is closer to 90.5% than 93.7%.